Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.

Composite photo of Cambodian people living the the forest, with a photo of a snake and of a pangolin © MORU 2020
An improvised village for forest workers, who sustain themselves with food gathered from the surrounding jungle.

Sponsored by University of Oxford and funded by the Global Fund Regional Component of the Regional Artemisinin-resistance Initiative (RAI2E) Grant, PAL is led by Principal Investigator Prof Richard Maude, with co-investigators MORU’s S. Sovannaroth, Tom Peto, James Callery, Mallika Imwong, Rupam Tripura, Mehul Dhorda, and Lorenz von Seidlein.

An estimated 2,000 participants who travel to the forest and stay overnight will receive either artemether-lumefantrine or multivitamin twice daily for 3 days followed by two doses weekly. They will be followed up every 28 days as they continue to visit the forest. Participants’ travel in the forest will be mapped to identify potential transmission sites and in-depth interviews conducted among forest goers, community leaders, healthcare workers and policymakers in Cambodia, Lao PDR and Thailand to assess the potential feasibility of prophylaxis in each country.

On 10 Feb, MORU and CNM organized an orientation meeting with the Provincial Health Department, Governor Office, local authorities, NGO partners, Village leaders and Village Malaria Workers to inform activities and aim of the PAL-Cambodia project. Following the site Initiation visit and training conducted by MORU’s Epidemiology and CTSG departments, the Cambodia team, led by Dr Rupam Tripura, has conducted engagement activities through schools and meetings with villagers.

Recruitment began on 10 March, and trial participants were given either artemether-lumefantrine or multivitamin and a mobile phone with a GPS logger installed for each group. Participants took pictures and shared some of the images while they stayed in the forest.

- Thank you, Rupam Tripura and James Callery for text and photos.

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.